Nessan Bermingham, the founding CEO of CRISPR drug maker Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]), is returning to Atlas Venture as a venture partner. Bermingham led Intellia from its incubation in the Cambridge, MA, venture capital firm through its 2016 initial public stock offering. Bermingham first joined Atlas in 2002. In his new role, Atlas said Bermingham will help the firm form new biotech companies.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
